Miltefosine: Great expectations against visceral leishmaniasis

Journal of Postgraduate Medicine

Volumn 49, Issue 1, 2003, Pages 101-103

  More, B ^a   Bhatt, H ^a   Kukreja, V ^b   Ainapure, S S ^b  

^a KEM HOSPITAL   (India)

^b LOKMANYA TILAK MUNICIPAL MEDICAL COLLEGE AND GENERAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTIAMEBIC AGENT; ANTIMONY DERIVATIVE; ANTINEOPLASTIC AGENT; MILTEFOSINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; BLADDER CANCER; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TISSUE LEVEL; ENTAMOEBA HISTOLYTICA; HEAD AND NECK CANCER; HUMAN; KIDNEY INJURY; LIVER TOXICITY; METABOLIC DISORDER; NAUSEA AND VOMITING; NONHUMAN; SKIN METASTASIS; SOFT TISSUE SARCOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; VISCERAL LEISHMANIASIS;

EID: 0037531280     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: 10.4103/0022-3859.911     Document Type: Article

References (27)

1. Gangneux JP. Treatment of visceral leishmaniasis: recent modalities. Presse Med 1999;28:2057-66.
2. Sundar S, Agarwal G, Ria M, Murray HW. Treatment of Indian visceral leishmaniasis with single dose or daily infusion of low dose liposomal amphotericin B, a randomized trial. BMJ 2002:25;323:419-22.
3. Hansjorg E. Miltefosine for visceral leishmaniasis. New Engl J Med 2000;342:894-5.
4. Sundar S, Gupta B, Makharia MK, Singh MK, Voss A, Rosenkiamer F, Engel J, Murray HW. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999:93;589-97
5. Lux H, Heise N, Klenner T, Hart D, Opperdoes FR. Ether-lipid ((alkylphospholipid) matabolism and the mechanism of action of ether - lipid analogues in visceral leishmania. Mol Biochem Parasitol 2000;111:1-14.
6. Murray HW, Delph- Etienne S. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in Tcells and activated macrophage microcidal mechanisms. J Inf Dis 2000;181:795-9.
7. Ruiter GA, Verheij M, Zerp SF, van Blitterswijk WJ. Alkyllysophospholipids as anticancer agents and enhancers of radiation induced apoptosis. Int J Radiat Oncol Biol Phy 2001;49:415-9.
8. Beckers T, Voegeli R, Hilgard P. Molecular and cellular effects of hexadecylphosphocholine (miltefosine) in human myeloid leukemic cell lines. Eur J Cancer 1994;30D:2143-50.
9. Henke J, Engekman J, Kutsher B, Nssner G, Engel J, Voegeli R, Leitofritz D. Changes of intracellular calcium, fatty acids and phospholipids during miltefosine-induced apoptosis monitored by fluorescence- and 13C NMR - spectroscopy. Anticancer Res 1999;19:4027-32
10. Murray HW. Suppression of post treatment recurrence of experimental visceral leishmaniasis in t- cell- deficient mice by oral miltefosine. Antimicrob Agents Chemother 2000;44:3235-6.
11. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fisher C, Voss A, Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999;341:1795-800.
12. Bresiser A, Kim DJ, Fleer EA, Damenz W, Drube A, Berger M, Nagel AG, Eibl H, Unger C. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids 1987;22:925-6.
13. Seifert K, Duchaene M, Werndorfer WH, Kollaritsch H, Scheiner, Wiedermann G, Hottkowitz, Eibl H. Effects of miltefosine and other alkylphosphocholines on human ingtestinal parasite entamoeba histolytica. Antimicrob Agents Chemother 2001;45:1505-10.
14. Mohan A, Seth S. Oral miltefosine in treatment of kala azar. Nat Med J Ind 2000;13:202-3.
15. Sundar S, Rosenkiamer F, Makharia MK, Mandal AK, Voss A, Hilgard P, Murray HW. Trial of miltefosine for visceral leishmaniasis. Lancet 1998;352:1821-3.
16. Thakur CP, Sinha PK, Singh KR, Hassan SM, Narain S. Miltefosine in a case of visceral leishmaniasis: and rising incidence of this disease in India. Trans R Soc Trop Med Hyg 2000;94:696-7.
17. Schmidt-Ott R, Klenner T, Overath P, Aebischer. Topical treatment with heaxdecylphosphocholine (miltex) efficiently reduces parasite in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1999;93:85-90.
18. Terwogt JM, Mandjes IA, Sindermann H, Beijnen JH, Hunink WWW. Phase II trial of topically applied miltefosine solution in patients with skin metastasized breast cancer. Br J Cancer 1999;79:1158-61
19. Konstantinov SM, Eibl H, Berger MR. BCR-ABL influences the antileukaemic efficacy of alkylphosphocholine. Br J Haematol 1999;107:365-80.
20. Konstantinov SM, Berger MR. Human urinary bladder carcinoma cell line respond to treatment with alkylphosphocholine. Cancer Left 1999;144:153-60.
21. Verweij J, Gandia, D, Planting AS, Stoter G, Armand JP. Phase II study of oral miltefosine in patients with squamous cell head and neck cancer. Eur J Cancer 1993;29A:778-9.
22. Verweij J, Planting AS, van der Burg M, Stoter G. A dose finding study of miltefosine (hexadecylphosphocholine) in patients with solid tumors. J Cancer Res Clin Oncol 1992;188:606-8.
23. Planting AS, Stoter G, Verweij J. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur J Cancer 1993;29A:518-9.
24. Verweij J, Krzemieniecki K, Kok T, Poveda A, Pottelsberghe C, Mouridsen H. Phase II study of oral Miltefosine (hexadecylphosphocholine) advanced sarcomas of adults-an EORTC soft tissue and bone sarcoma group study. Eur J Cancer 1993;29A:208-9.
25. Smorenburg CH, Seynaevec, Bontenbal M, Planting AS, Sindermann H, Verweij J. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. Anticancer Drugs 2000;11:825-8.
26. Clive S, Gardiner J, Leonard RC. Miltefosine as topical treatment for cutaneous metastases in breast carcinoma. Cancer Chemother Pharmacol 1999;44:S29-30.
27. Sundar S, Makharia A, More DK, Agarwal G, Voss A, Bachmann P, Murray HW. Oral treatment of visceral leishmaniasis with miltefosine. Clin Inf Dis 2000:93:589-97.